Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 15/20 | 0.57 |
| ▸ | MMP1 | P03956 | 14/20 | 0.57 |
| ▸ | MMP9 | P14780 | 12/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.57 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | MMP7 | P09237 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7578043 | 0.88 | HRH3 (0.54) | MMP13MMP1MMP9ADAM17HRH3 | |
| SCHEMBL7512979 | 0.87 | MMP1 (0.57) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL7505164 | 0.84 | MMP1 (0.58) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL7570327 | 0.84 | MMP1 (0.53) | MMP13MMP1MMP9ADAM17HRH3 | |
| Hydroxyamine SCHEMBL7661687 | 0.83 | MMP1 (0.51) | MMP13MMP1MMP9ADAM17HRH3 | |
| SCHEMBL7529490 | 0.82 | MMP13 (0.55) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL7504704 | 0.82 | HRH3 (0.56) | MMP13MMP1MMP9ADAM17HRH3 | |
| SCHEMBL7509176 | 0.81 | MMP1 (0.51) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL7618861 | 0.80 | MMP1 (0.54) | MMP13MMP1MMP9ADAM17MMP3 | |
| Hydroxyamine SCHEMBL7459041 | 0.79 | HRH3 (0.52) | MMP13MMP1MMP9ADAM17HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP13 27/4885MMP1 4/4885MMP9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.